Oramed Pharmaceuticals Inc (ORMP) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Oramed Pharmaceuticals Inc  (NASDAQ: ORMP)
 

Oramed Pharmaceuticals Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ORMP Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) - 14.14 % 10.18 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) - -1.07 % -2.46 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) - 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) - 2.69 % 2.1 % 2.61 %
Revenue 5 Year Average Growth -5.9 % 7.52 % 8.67 % 13.63 %


ORMP's Growth Comparisons in III. Quarter 2026




Oramed Pharmaceuticals Inc reported top-line of $ 0 millions in the third quarter 2026, compare to $ 0 millions in the same quarter a year ago. Revenues in the Major Pharmaceutical Preparations industry grew by 14.14%, while the top-line in the Healthcare sector increased by 10.18%, and overall market improved by 10.9% from the third quarter 2025.

Sequentially company's Revenue were unchanged from the second quarter results. . Looking into annual growth, sales grew by -5.9% on average in last five years, while S & P 500's including only Businesses with the third quarter 2026 earnings reports, average yearly sales growth is 13.63%.

ORMP Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential


Growth Rates of ORMP's Income in the third quarter 2026


ORMP Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - 4.19 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) - -23.95 % -12.21 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) - 30.78 % 30.98 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) - -2.24 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change - 14.12 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) -61.95 % -16.85 % -38.86 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) -76.44 % -26.31 % -63.27 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) 230.4 % 6.26 % 9.88 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) -17.14 % -9.98 % -4.67 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - 14.58 % 8.91 % -28.64 %

ORMP Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) -61.95 % -17.47 % -39.2 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) -76.44 % 21.94 % 11.78 % 27.07 %
Y / Y Net Income Change (Q3 TTM) 230.4 % 5.06 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) -17.14 % -10.2 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth - 14.16 % 9.09 % 23.95 %

ORMP's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) -62.07 % -31.09 % -38.86 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) -76.84 % -35.27 % -63.27 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) 239.08 % - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) -16.98 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 22.26 % -0.46 % 8.91 % -28.64 %



ORMP EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) -61.95 % -31.6 % -39.2 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) -76.63 % 7.1 % 11.78 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) -16.99 % 0.05 % 10.63 % 4.93 %
EPS Net 5 Year Avg. Change 21.78 % 14.16 % 9.09 % 23.95 %



As Oramed Pharmaceuticals Inc's income per share faded by -61.95% year on year in the third quarter, Major Pharmaceutical Preparations industry fell only by -31.6%, Oramed Pharmaceuticals Inc's third quarter performance was trailing Major Pharmaceutical Preparations, and underperformed the -39.2% EPS slide in the Healthcare sector. Weak third quarter income per share, in Major Pharmaceutical Preparations industry and within the Healthcare sector, were reflected in Oramed Pharmaceuticals Inc results which underperformed overall market.

Bottom-line fell by -76.63% from the second quarter results. Comparing the annual growth, income per share of 21.78% on average in last five years, to the S & P 500's, including only Businesses with the third quarter 2026 earnings, average yearly income per share growth is 23.95%. Oramed Pharmaceuticals Inc grew less than the market.

ORMP Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - 25.56 % 44.26 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) - -29.98 % -42.65 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) - 12.44 % 19.33 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) - 3.57 % 5.88 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 0.88 % 0.41 % 1.8 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) - 18.43 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) - -21.14 % -19.32 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) -50 % 15.58 % 9.34 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) 0 % 1.87 % 0.99 % 23.05 %
Capital Expenditures 5 Year Avg. Change -35.72 % 7.84 % 8.61 % 14.19 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.